Drugs / CG001419
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06636500 | Jan → Dec 2025 | — | Cullgen Australia Pty Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07394374 | Jun 2023 → Aug 2030 expected | NTRK fusion positive cancer | Cullgen (Shanghai),Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-12-12 | Cullgen (Shanghai),Inc | Results Cullgen Reports Positive Results from Phase 1 Study of its Novel Non-Opioid Product Candidate CG001419 for Pain cullgen.com ↗
Results from the study showed that all doses were well-tolerated with no drug-related serious adverse events observed. |
| 2024-11-13 | Cullgen (Shanghai),Inc | Results PULMATRIX AND CULLGEN ANNOUNCE PROPOSED MERGER cullgen.com ↗
With respect to the cancer trial, Cullgen has dosed ten patients thus far with no observed dose-limiting toxicity, treatment-related serious adverse events or grade ≥ 3 treatment related adverse events. |
| 2022-08-09 | Cullgen (Shanghai),Inc | Regulatory Cullgen Announces Chinese NMPA Allowance of Investigational New Drug Application of TRK Degrader to Begin Clinical Trials cullgen.com ↗ |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-12-12 | Cullgen (Shanghai),Inc | Cullgen Reports Positive Results from Phase 1 Study of its Novel Non-Opioid Product Candidate CG001419 for Pain cullgen.com ↗ |
| 2025-09-18 | Cullgen (Shanghai),Inc | Cullgen Completes Enrollment in Phase 1 Trial of its Novel Non-Opioid Pain Product Candidate CG001419 cullgen.com ↗ |
| 2024-11-13 | Cullgen (Shanghai),Inc | PULMATRIX AND CULLGEN ANNOUNCE PROPOSED MERGER cullgen.com ↗ |
| 2023-07-27 | Cullgen (Shanghai),Inc | Cullgen Announces First-In-Human Dose in Phase I/II Trial of CG001419, a First-in-Class TRK Protein Degrader for Treatment of Cancer Patients cullgen.com ↗ |
| 2022-08-09 | Cullgen (Shanghai),Inc | Cullgen Announces Chinese NMPA Allowance of Investigational New Drug Application of TRK Degrader to Begin Clinical Trials cullgen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CG001419 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06636500 ↗ |
| Route | Oral | “Oral doses” NCT06636500 ↗ |